Oscar Health, Inc. (OSCR) Stock Analysis
Is OSCR a good investment?
Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 57.0/100 as of August 22, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet with $8.56B cash, $692.5M FCF, and D/E of 0.21x (vs industry 0.672x) — 69% below industry leverage — provides unmatched financial resilience, regulatory capital buffer, and strategic optionality that peers cannot match. Main concern: CRITICAL VALUATION: Stock at $32.04 is 3.9% ABOVE analyst consensus target of $30.82 — negative expected return to fair value with zero margin of safety; imputed fair P/E of ~20.7x (using industry PEG 1.98x × 10.45% forward EPS growth) implies 31% discount to industry average P/E of 29.98x is warranted, making current price materially overvalued on a growth-adjusted basis.
Investment Summary
Oscar Health (OSCR) at $32.04 remains modestly above the analyst consensus target of $30.82, implying -3.8% downside to fair value with no margin of safety. The company's fundamentals are genuinely bifurcated: exceptional financial health (D/E of 0.21x vs industry 0.672x, $8.56B cash, $692.5M FCF) and profitability leadership (ROE 34.3% vs industry 8.3%, Operating Margin 7.96% vs industry 4.30%, Net Margin 3.60% vs industry 1.12%) coexist with a critical forward growth deficit — Next Year EPS Growth of only 10.45% versus the industry average of 40.89%, meaning peers are growing earnings nearly 4x faster. News sentiment is strongly positive (97.3/100): Q2 earnings beat estimates, the company raised its full-year 2026 outlook, and administrative expense ratios declined — all confirming the profitability transition is real. However, this excellent news is already priced in at current levels above analyst consensus. The stock has declined -2.2% from $32.76 to $32.04 since our prior Sell recommendation, but remains above the $28.00-$30.00 re-entry zone we identified. Risk/reward remains unfavorable at current prices.
Key Strengths
- Fortress balance sheet with $8.56B cash, $692.5M FCF, and D/E of 0.21x (vs industry 0.672x) — 69% below industry leverage — provides unmatched financial resilience, regulatory capital buffer, and strategic optionality that peers cannot match
- Profitability leadership across all metrics: ROE 34.3% (+313% vs industry 8.3%), Operating Margin 7.96% (+85% vs industry 4.30%), Net Margin 3.60% (+222% vs industry 1.12%) — all achieved with minimal leverage, confirming genuine operational efficiency; Q2 2026 EPS beat ($1.10 vs $0.43 consensus, +156%) and raised full-year 2026 outlook confirm the profitability transition is durable
- Strong positive news momentum (97.3/100 sentiment): Company raised full-year 2026 financial outlook, lower administrative expense ratios signal improving scalability, consecutive profitable periods demonstrate the ACA marketplace tech-enabled model is working — historical Revenue Growth of 70.4% vs industry 19.83% confirms extraordinary market share capture
Key Concerns
- CRITICAL VALUATION: Stock at $32.04 is 3.9% ABOVE analyst consensus target of $30.82 — negative expected return to fair value with zero margin of safety; imputed fair P/E of ~20.7x (using industry PEG 1.98x × 10.45% forward EPS growth) implies 31% discount to industry average P/E of 29.98x is warranted, making current price materially overvalued on a growth-adjusted basis
- FORWARD GROWTH DEFICIT: Next Year EPS Growth of 10.45% vs industry average 40.89% — peers growing earnings nearly 4x faster than OSCR; this dramatic deceleration from 272.8% historical EPS growth to 10.45% forward, while industry peers project 40.89%, removes any justification for a premium multiple and argues for a 30-40% discount to industry P/E
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
OSCR's fundamentals present a tale of two stories. On the positive side: ROE of 34.3% is extraordinary versus the industry average of 8.3% (+313% premium), achieved with minimal leverage (D/E 0.21x vs industry 0.672x), confirming pure operational efficiency. Operating Margin of 7.96% exceeds the industry average of 4.30% by 85%, and Net Margin of 3.60% triples the industry average of 1.12%. The balance sheet is fortress-grade: $8.56B in cash, $692.5M in free cash flow, and D/E of 0.21x eliminate financial distress risk entirely. Historical Revenue Growth of 70.4% vs industry 19.83% (+255%) demonstrates extraordinary market penetration. On the negative side: Forward Next Year EPS Growth of 10.45% is 74.4% below the industry average of 40.89% — the single most critical forward-looking metric shows severe underperformance versus peers. P/E and PEG ratios are unavailable, but imputing a PEG using the industry average of 1.98x × 10.45% EPS growth implies a fair P/E of only ~20.7x — a 31% discount to the industry average P/E of 29.98x. P/B of 4.75x is defensible given the 34.3% ROE but assumes sustained profitability. The analyst consensus target of $30.82 implies -3.8% downside from current price, confirming the stock is modestly overvalued relative to analyst fair value estimates.
News Sentiment
Oscar Health is on a roll — and Wall Street is taking notice. The ACA marketplace insurer just delivered another quarter of impressive profits, with Q2 earnings crushing analyst expectations as member costs eased and the company's tech-driven approach to healthcare management continued to pay dividends. The headline 'Oscar Health Reports Another Big Profit As Obamacare Member Costs Ease' tells the core story: the company's bet on the Affordable Care Act marketplace is working. Lower medical costs among members, combined with declining administrative expense ratios, are translating directly into fatter profits — a combination that has investors excited. The company didn't just beat estimates — it raised its full-year 2026 financial outlook, signaling management's confidence that the good times will continue. The Q2 Earnings Call Highlights revealed that consecutive profitable periods are becoming the new normal for a company that was burning cash just a few years ago. Analysts have responded positively, with Strong Buy rankings reflecting upward earnings estimate revisions. The 'Best Growth Stocks to Buy for August 20th' mention suggests OSCR is appearing on institutional radar screens. For everyday investors, the message is clear: Oscar Health has successfully transformed from a money-losing startup into a genuine profit machine. The question now is whether the stock — already trading above what analysts think it's worth — has gotten ahead of itself. The fundamentals are improving, but at $32 per share, much of the good news may already be baked in.
Risk Assessment
PRIMARY RISK: Valuation risk is the dominant concern — at $32.04, the stock trades 3.9% above analyst consensus target of $30.82, meaning the expected return to fair value is negative before any margin of safety. If the stock reverts to analyst consensus, that is a -$1.22 loss per share (-3.8%). SECONDARY RISK: Forward growth deceleration — if 10.45% EPS growth disappoints further or medical loss ratios deteriorate, the stock could re-rate sharply lower toward the imputed fair P/E of ~20.7x. TERTIARY RISK: Regulatory risk in ACA marketplace — any policy changes to Obamacare subsidies or enrollment rules could materially impact OSCR's primary revenue source. MITIGATION: The $8.56B cash fortress and 0.21x D/E provide substantial downside protection against operational shocks. The company's improving administrative expense ratios and consecutive profitable quarters reduce near-term earnings risk. UPSIDE RISK (to the bear case): If forward EPS growth accelerates beyond 10.45% — perhaps driven by continued administrative efficiency gains — the stock could re-rate higher. The Q2 beat of $1.10 vs $0.43 consensus (+156%) suggests analyst estimates may be too conservative. STOP LOSS: $25.50 represents approximately 11% below the lower entry bound of $28.75, providing a defined risk parameter.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is OSCR a halal stock?
No, Oscar Health, Inc. (OSCR) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for OSCR?
Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 57.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is OSCR a good investment?
According to Plutrex AI, OSCR has a Hold rating (57.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in OSCR?
US stocks like OSCR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in OSCR?
Plutrex AI identifies the main risks for OSCR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.